For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com
Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018
TOKYO, Japan (February 23, 2018) – Daiichi Sankyo Company, Limited, today announced the following organizational changes taking place from April 1, 2018.
- Daiichi Sankyo Co., Ltd.
(1) Corporate
Establish “External Affairs Department” to enhance industry-wide activities.
(2) Sales & Marketing Division
Rename “Marketing Department” to “Primary Marketing Department”, and establish “Specialty Marketing Department”. “Specialty Marketing Department” will focus on building sales & marketing structure for the development pipeline, centering on specialty oncology products.
(3) R&D Division
Reorganize departments under “Oncology Function” to further enhance the progress in development in oncology. Rename “Rare Disease & LCM Laboratories” to “Rare Disease Laboratories”. LCM (Life Cycle Management) activities will be decentralized and managed by relevant Laboratories within R&D Division based on therapeutic areas.
(4) Biologics Division
Transfer research function on innovative vaccines from Kitasato Daiichi Sankyo Vaccine Co., Ltd. to form “Vaccine Research Laboratories”. The laboratories will maximize the synergistic effect of biologics and vaccine technology to accelerate research activities in this arena.
(5) Quality & Safety Management Division
Reorganize relevant departments so that “Pharmacovigilance Department” and newly established “Post Marketing Study Department” will be clearly responsible for PV and PMS activities, respectively. The two departments will be overseen and governed by “Safety and Risk Management Department”.
The new structure will enhance safety and risk management capabilities to address change in product portfolio as well as increase in the number of products and pipeline.
Functions from Asubio Pharma Co., Ltd will be transferred and absorbed into “R&D Division” and “Biologics Division”.
- Daiichi Sankyo Espha Co., Ltd.
(1) Corporate Strategy Department
Evolve “Product Planning Department” to “Corporate Strategy Department”. The new department will orchestrate business strategy and product development to realize mid-term management strategies.
(2) Sales & Marketing Division
Reorganize the existing two “Sales Promotion Departments” (East Japan and West Japan) into four departments. (East Japan, Capital Region, Tokai & Kinki, and West Japan). The new structure will further address customer needs based on the progress of the integrated community care system in Japan.
- Daiichi Sankyo Healthcare Co., Ltd.
(1) International Sales Department
Establish “International Sales Department” under the President’s direct report. The new department will develop and execute international business strategy to enhance product lineups and make new market entries centered on previously entered markets in Asia.